Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098021 | 0.86 | NR1H2 (0.49) | BACE1KDM4EPKMMAPTTHRB | |
| SCHEMBL6150378 | 0.84 | BACE1 (0.51) | BACE1KDM4EPKMMAPTTHRB | |
| SCHEMBL15600102 | 0.83 | KDM4E (0.47) | BACE1KDM4EPKMFPR2PTPN2 | |
| SCHEMBL15600079 | 0.83 | KDM4E (0.47) | BACE1KDM4EPKMFPR2PTPN2 | |
| SCHEMBL12635860 | 0.82 | KDM4E (0.56) | BACE1KDM4EPKMFPR2GPR119 | |
| SCHEMBL20057287 | 0.81 | KDM4E (0.46) | BACE1KDM4EPKMMAPTTHRB | |
| SCHEMBL15600188 | 0.80 | ACKR3 (0.45) | BACE1KDM4EPKMMAPTPTPN2 | |
| SCHEMBL5573169 | 0.79 | HPGD (0.53) | KDM4EPKMMAPTTHRBGPR119 | |
| SCHEMBL21263570 | 0.79 | FEN1 (0.43) | MAPT | |
| SCHEMBL2979718 | 0.79 | BACE1 (0.47) | BACE1KDM4EPKMMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2019-10-22 | — | — | US | disclosed |
| WO-2019154120-A1 | CYTOTOXIC AGENT AND CONJUGATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2018-06-14 | — | — | US | disclosed |
| EP-3308801-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | XDCExplorer (Shanghai) Co., Ltd. (CN) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10449258-B2 | Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof | FCGR3B, SI, INCENP | BACE1 2201/4885KDM4E 3451/4885PKM 3888/4885 |
| US-20180161446-A1 | ANTIBODY DRUG CONJUGATE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USES THEREOF | FCGR3B, SI, INCENP | BACE1 2201/4885KDM4E 3451/4885PKM 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.